^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    pumitamig (BNT327)

    i
    Other names: BNT327, BMS986545, PM8002, PM 8002, PM-8002, BNT 327, BNT-327, BMS-986545
    Company:
    BMS, BioNTech
    Drug class:
    PD-L1 inhibitor, VEGF-A inhibitor
    Related drugs:
    3d
    A Clinical Trial Testing the Safety of BNT327 (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer (clinicaltrials.gov)
    P2, N=105, Not yet recruiting, BioNTech SE
    New P2 trial
    |
    gemcitabine • albumin-bound paclitaxel • irinotecan • pumitamig (BNT327)
    8d
    BNT327-03: Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer (clinicaltrials.gov)
    P3, N=621, Recruiting, BioNTech SE | Active, not recruiting --> Recruiting | N=439 --> 621 | Trial completion date: Sep 2028 --> Mar 2029 | Trial primary completion date: Apr 2028 --> Dec 2028
    Enrollment open • Enrollment change • Trial completion date • Trial primary completion date
    |
    cisplatin • Tecentriq (atezolizumab) • carboplatin • etoposide IV • pumitamig (BNT327)
    20d
    ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer (clinicaltrials.gov)
    P3, N=558, Recruiting, BioNTech SE | Not yet recruiting --> Recruiting
    Enrollment open
    |
    carboplatin • gemcitabine • albumin-bound paclitaxel • Halaven (eribulin mesylate) • pumitamig (BNT327)
    1m
    A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer (clinicaltrials.gov)
    P2/3, N=990, Not yet recruiting, Bristol-Myers Squibb
    New P2/3 trial
    |
    Avastin (bevacizumab) • 5-fluorouracil • irinotecan • leucovorin calcium • pumitamig (BNT327)
    1m
    ROSETTA GI 204: A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (clinicaltrials.gov)
    P2/3, N=690, Not yet recruiting, Bristol-Myers Squibb
    New P2/3 trial
    |
    Opdivo (nivolumab) • 5-fluorouracil • pumitamig (BNT327)
    1m
    BNT326-02: A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P1/2, N=420, Recruiting, BioNTech SE | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Keytruda (pembrolizumab) • carboplatin • paclitaxel • pumitamig (BNT327) • BNT326 • MK-3475 SC
    2ms
    A First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=375, Recruiting, BioNTech SE | Not yet recruiting --> Recruiting
    Enrollment open • First-in-human
    |
    pumitamig (BNT327)
    3ms
    ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer (clinicaltrials.gov)
    P3, N=558, Not yet recruiting, BioNTech SE
    New P3 trial
    |
    carboplatin • gemcitabine • albumin-bound paclitaxel • Halaven (eribulin mesylate) • pumitamig (BNT327)
    3ms
    DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors (clinicaltrials.gov)
    P2, N=492, Recruiting, DualityBio Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    pumitamig (BNT327) • BNT324
    3ms
    A First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=375, Not yet recruiting, BioNTech SE
    New P1/2 trial
    |
    pumitamig (BNT327)
    3ms
    BNT326-01: A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors (clinicaltrials.gov)
    P1/2, N=550, Recruiting, BioNTech SE | Not yet recruiting --> Recruiting
    Enrollment open
    |
    itraconazole • pumitamig (BNT327)
    3ms
    BNT327-02: Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy (clinicaltrials.gov)
    P2, N=100, Recruiting, BioNTech SE | N=70 --> 100 | Trial completion date: Sep 2028 --> Jun 2029 | Trial primary completion date: Nov 2027 --> Aug 2028
    Enrollment change • Trial completion date • Trial primary completion date
    |
    carboplatin • gemcitabine • paclitaxel • albumin-bound paclitaxel • Halaven (eribulin mesylate) • pumitamig (BNT327)